Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix
Synopsis
Cullinan Therapeutics secured global rights, excluding Greater China, to velinotamig from Genrix Bio, expanding its autoimmune pipeline with a second T cell engager.
Shares of Cullinan Therapeutics Inc. fell in after-hours trading despite the company announcing a licensing agreement with Genrix Bio to develop velinotamig, a clinical-stage BCMA-directed bispecific T cell engager, for autoimmune diseases.
The stock closed 1.2% higher at $9.07 on Tuesday before slipping 5.7% to $8.55 in after-hours trading.
The deal grants Cullinan exclusive global rights, excluding Greater China, to velinotamig across all indications, with a $20 million upfront payment and potential milestone and royalty payments exceeding $692 million.
The addition of velinotamig expands Cullinan’s autoimmune pipeline, alongside its CD19-targeting TCE, and is expected to support the company’s cash runway into 2028.
Cullinan plans to leverage data from Genrix’s upcoming Phase 1 study in China to accelerate global development.
CEO Nadim Ahmed said velinotamig could offer a “precise and potentially disease-modifying approach” by targeting self-reactive plasma cells implicated in certain autoimmune diseases.
On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.
The stock has declined 26.8% so far in 2025.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.